BioSpace News Archive

NeuroPace, Inc., a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, announced its participation in the following upcoming investor conferences:

Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced that its management team will present at the following investor conferences.

Gracell Biotechnologies Inc. announced that the management team will participate in and attend one-on-one meetings at two upcoming investor conferences.

Collegium Pharmaceutical, Inc. announced that the U.S. Food and Drug Administration has granted New Patient Population exclusivity for Nucynta®, an immediate release formulation of tapentadol.

China Medical System Holdings Limited announced that the Group entered into a Collaboration Agreement with Nanjing NeuroDawn Pharmaceutical Co. Ltd., for anti-ischemic stroke brain cytoprotectant and class 1 innovative drug Y-3 injection, and gained an exclusive promotion right of the Product in Mainland China, Hong Kong Special Administrative Region and Macao Special Administrative Region.

Fresenius Kabi and Lupagen Inc. announced the companies have entered into a development and supply agreement for technologies designed to bring the delivery of cell and gene therapies to the bedside.

Avinger, Inc. announced three podium presentations featuring the company’s Lumivascular technology at The Amputation Prevention Symposium, held from August 16 through August 19 in Chicago, Illinois.

Ceramedix Holding, LLC (Ceramedix) today announced it was awarded a $3,007,043 Phase 2B National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grant to evaluate the non-clinical pharmacology of its lead drug candidate.

EmpiRx Health, the leading value-based PBM company, applauds Blue Shield of California for joining it in implementing a value-based pharmacy care model.

Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will present at two healthcare industry conferences in September 2023.